REVIEW 3 major objections 6 minor 5 references
Advancing Precision Oncology Through Modeling of Longitudinal and Multimodal Data
T0 review · 3 major / 6 minor · reviewed 2026-08-08 · deepseek-v4-flash
Pith's one-line read This review argues that precision oncology should be built on longitudinal multimodal biomarkers—repeated measurements of clinical, molecular, imaging, and histology data—rather than single-timepoint, single-modality snapshots, because…
desk verdict A solid, useful review of longitudinal multimodal modeling in oncology, but the conclusion overstates what the surveyed evidence shows. read the letter →
The pith
A machine-rendered reading of the paper's core claim, the machinery that carries it, and where it could break.
The reading
What carries the argument
The load-bearing object is the longitudinal multimodal biomarker: a patient's serial measurements across clinical records, molecular assays, medical images, and histology, viewed as a trajectory rather than isolated points. The review's argument is carried by a taxonomy of techniques for turning these trajectories into predictions: handcrafted temporal features (concatenation, change features, functional PCA, dynamic time warping), statistical models (mixed effects, parametric empirical Bayes, dynamic Bayesian networks, hidden Markov models, Gaussian processes), and deep learning (RNNs, temporal convolutional networks, Transformers, self-supervised and reinforcement learning). For combining modalities, it distinguishes early, intermediate, and late fusion and stresses that temporal ordering and causal relationships across modalities must be preserved. The taxonomy does the work of showing that longitudinal and multimodal modeling is a mature, multi-tool discipline rather than a single method, and of locating where current studies fall short.
What would settle it
Run a systematic benchmark on one cancer screening task (e.g., lung nodule malignancy or ovarian cancer detection) comparing longitudinal multimodal models against the best single-timepoint, single-modality model on the same cohort, with identical evaluation protocols. If the longitudinal multimodal models do not meaningfully improve metrics such as AUROC or calibration, the claim that this analysis is 'crucial' would be falsified.
Extended reading notes
Core claim
The paper's central claim is stated plainly in its conclusion: longitudinal and multimodal analysis is crucial for advancing precision oncology because it provides a comprehensive assessment of cancer complexity and heterogeneity. The authors argue that cross-sectional, single-modality analysis captures only a snapshot of the disease and misses the temporal patterns of progression, treatment response, and resistance that serial data reveal. They support this by reviewing evidence that longitudinal modeling of blood biomarkers outperforms single-threshold screening rules, that multimodal integration adds complementary information for risk assessment and therapy targeting, and that the two can be combined. They also catalog the field's open problems—irregular sampling, temporal alignment across modalities, limited data and labels, interpretability, and the absence of standardized evaluation against simple baselines—and argue that solving these is necessary for early detection and personalized treatment.
Load-bearing premise
The load-bearing premise is that adding temporal depth and multiple data modalities will actually improve clinical predictions and decisions enough to justify the extra cost and complexity; the paper itself notes that few studies compare such models against single-timepoint or single-modality baselines.
Editorial extensions
If this is right
- Screening programs that currently use single-threshold biomarker rules should move to serial biomarker algorithms, since the reviewed evidence shows individualized longitudinal thresholds detect cancers earlier at the same specificity.
- Prognostic models should incorporate repeated imaging and molecular measurements (e.g., delta-radiomics, serial circulating tumor DNA) rather than baseline values alone to predict response, recurrence, and survival.
- Multimodal fusion should be designed to respect the actual acquisition times of each modality and their causal ordering, rather than naively synchronizing or concatenating all data.
- Evaluation of new models should include ablations and comparisons against single-timepoint and single-modality baselines to demonstrate the value of added complexity.
- Building large, shareable longitudinal oncology datasets and using self-supervised pretraining on unlabeled serial data would accelerate the field, as these approaches address the scarcity of labeled longitudinal data.
Reading between the lines
- If the paper's thesis is right, the marginal clinical value of a new data collection should be measured as the improvement in predictive performance per additional timepoint and per additional modality, which would give a principled basis for deciding how often to scan or biopsy a patient.
- The same longitudinal multimodal modeling stack could be applied to non-oncologic chronic diseases whose data are already collected serially, such as cardiometabolic or autoimmune conditions, where trajectory-based risk models may outperform single-visit assessments.
- A testable extension would be to use causal models across modalities—e.g., linking early molecular changes to later imaging phenotypes—to generate mechanistic hypotheses about tumor evolution rather than purely correlational predictions.
- The review's emphasis on irregular time intervals suggests that models explicitly encoding elapsed time (time-aware RNNs, neural ODEs, Gaussian process adapters) will become increasingly central; a direct benchmark across these on oncology data would clarify which handles real-world schedules best.
Editorial analysis
A structured set of objections, weighed in public.
Referee Report
Summary. The paper is a narrative review of longitudinal and multimodal modeling for precision oncology. It surveys four data modalities (clinical, molecular, imaging, and histology), describes feature engineering, statistical, and deep learning methods for longitudinal data, outlines multimodal fusion strategies, and reviews applications in diagnosis and prognosis. It concludes that longitudinal and multimodal analysis is 'crucial' for advancing precision oncology, while also cataloguing challenges such as data acquisition, irregular sampling, temporal alignment, model selection, explainability, and evaluation.
Significance. As a survey, the paper offers a useful structured overview with clear figures, a pros/cons table for modeling techniques, a supplemental table of public longitudinal cancer datasets, and a generally transparent discussion of known limitations. If its central thesis is accepted, it would help motivate a research program centered on longitudinal multimodal biomarkers. However, the evidence base surveyed does not yet establish that such models outperform simpler single-timepoint or single-modality baselines; the paper is best read as proposing a research agenda rather than demonstrating a proven clinical benefit. A notable strength is that Section VI.I explicitly identifies the absence of controlled comparisons as a key gap.
major comments (3)
- [VII (Conclusion) and VI.I] The conclusion states that longitudinal and multimodal analysis is 'crucial' for advancing precision oncology, but Section VI.I acknowledges that 'additional evaluation must be performed to justify the longitudinal and multimodal components' and that few studies compare against single-timepoint or single-modality baselines. The surveyed evidence supports longitudinal multimodal modeling as a promising direction, not as an established necessity. The conclusion should be revised to frame this as a hypothesis or research priority, and it should explicitly tie back to the evaluation gap identified in Section VI.I.
- [VI.G and overall methodology] The review does not present a systematic search protocol or explicit inclusion/exclusion criteria, and it draws on a selective set of references for its claim that longitudinal analysis outperforms cross-sectional analysis (Section I, refs [3]-[12]). Section VI.G concedes that 'very few compare results across feature engineering, statistical methods, and DL models simultaneously.' Given this, the strong comparative claim at the outset is not supported by the review's own evidence. The paper should be clearly labeled as a narrative review, and passages that assert superiority over cross-sectional or single-modality methods should be qualified to reflect the lack of systematic comparative evidence.
- [V (Applications)] The applications section reports individual studies but does not critically assess whether those studies include appropriate comparator baselines. For example, the statement that 'early fusion of longitudinal clinical and medical imaging data ... has exhibited enhanced efficacy in cancer diagnosis' is supported by a single citation [118] with no discussion of what it was compared against. This is consistent with the general evaluation gap noted in Section VI.I, but it should be acknowledged at the point of each such claim rather than implied as established fact.
minor comments (6)
- [Section III / Tables] The 'Advantages and Disadvantages of Longitudinal Modeling Techniques' content appears twice in the manuscript, once labeled as Table II and once as Table I, with identical rows; the duplicate should be removed and the remaining table renumbered consistently.
- [Section III.C.3] The text refers to '(Fig. 3H)' for reinforcement learning, but the Fig. 3 caption labels the reinforcement learning panel as (G); the cross-reference should be corrected.
- [Section VI.H] The phrase 'as discussed in Section H' should read 'as discussed in Section VI.H' or 'as discussed in Section III,' since the section is numbered within the sixth major section of the paper.
- [References] Reference [81] is incomplete: it gives only '2014' with no journal, volume, or pages, and it appears to duplicate reference [75]; the bibliography should be consolidated.
- [Supplemental Table I] The column header labeled 'Histology' contains entries such as 'Whole Slide Image' in plural/inconsistent forms; unify the terminology (e.g., 'Whole-slide images') for consistency.
- [Front matter] The abstract appears twice in the submitted file, once at the top and again before the Index Terms; this is likely a formatting artifact, but the duplicate should be removed before publication.
Circularity Check
No circularity: this is a review paper that surveys existing methods and makes no derivation whose conclusion is presupposed by its inputs.
full rationale
This manuscript is a narrative review of longitudinal and multimodal modeling in precision oncology. It does not derive new equations, fit parameters, or present experimental predictions. Its central claim is that longitudinal and multimodal analysis is important, supported by a survey of prior studies and by the paper's own framing of complementary modalities. The authors do cite their own prior work (e.g., Skates et al. and related ovarian and hepatocellular carcinoma screening algorithms), but these citations are used as concrete examples of existing methods, not as the sole justification for the review's thesis. The conclusion is not forced by a self-citation chain or by definition. The paper even acknowledges a key limitation in Section VI.I: 'additional evaluation must be performed to justify the longitudinal and multimodal components' and notes that few studies compare against single-timepoint or single-modality baselines. That is an evidence gap or overstatement relative to the conclusion, not a circular dependency. No step in the paper reduces a claimed result to its own inputs, so the appropriate circularity score is 0.
Assumptions & free parameters
assumptions (2)
- domain assumption Longitudinal data provide predictive information beyond cross-sectional snapshots.
- domain assumption The cited literature is representative of the field.
Cite this review
Pith. "Pith review of Advancing Precision Oncology Through Modeling of Longitudinal and Multimodal Data." pith.science (2026). https://pith.science/paper/WCM3M5J3
@misc{pith2026250207836,
author = {Pith},
title = {Pith review of: Advancing Precision Oncology Through Modeling of Longitudinal and Multimodal Data},
year = {2026},
howpublished = {\url{https://pith.science/paper/WCM3M5J3}},
note = {Machine review of arXiv:2502.07836}
}
read the original abstract
Cancer evolves continuously over time through a complex interplay of genetic, epigenetic, microenvironmental, and phenotypic changes. This dynamic behavior drives uncontrolled cell growth, metastasis, immune evasion, and therapy resistance, posing challenges for effective monitoring and treatment. However, today's data-driven research in oncology has primarily focused on cross-sectional analysis using data from a single modality, limiting the ability to fully characterize and interpret the disease's dynamic heterogeneity. Advances in multiscale data collection and computational methods now enable the discovery of longitudinal multimodal biomarkers for precision oncology. Longitudinal data reveal patterns of disease progression and treatment response that are not evident from single-timepoint data, enabling timely abnormality detection and dynamic treatment adaptation. Multimodal data integration offers complementary information from diverse sources for more precise risk assessment and targeting of cancer therapy. In this review, we survey methods of longitudinal and multimodal modeling, highlighting their synergy in providing multifaceted insights for personalized care tailored to the unique characteristics of a patient's cancer. We summarize the current challenges and future directions of longitudinal multimodal analysis in advancing precision oncology.
Figures
Reference graph
Works this paper leans on
-
[22]
Multi-omic machine learning predictor of breast cancer therapy response,
S.-J. Sammut et al., “Multi-omic machine learning predictor of breast cancer therapy response,” Nature, vol. 601, no. 7894, pp. 623–629, Jan. 2022. [23] M. R. Cowie et al., “Electronic health records to facilitate clinical research,” Clin. Res. Cardiol., vol. 106, no. 1, pp. 1–9, Jan. 2017. [24] A. J. Read et al., “Prediction of Gastrointestinal Tract Can...
work page 2022
-
[66]
M. Moor et al., “Early Recognition of Sepsis with Gaussian Process Temporal Convolutional Networks and Dynamic Time Warping,” in Proceedings of the 4th Machine Learning for Healthcare Conference, PMLR, Oct. 2019, pp. 2–26. [67] A. Giannoula et al., “Identifying temporal patterns in patient disease trajectories using dynamic time warping: A population-base...
arXiv 2019
-
[109]
F. Ma et al., “Dipole: Diagnosis Prediction in Healthcare via Attention-based Bidirectional Recurrent Neural Networks,” in Proceedings of the 23rd ACM SIGKDD International Conference on Knowledge Discovery and Data Mining, in KDD ’17. New York, NY, USA: Association for Computing Machinery, Aug. 2017, pp. 1903–1911. [110] S. Bai et al., “An Empirical Evalu...
arXiv 2017
-
[141]
and The Cancer Imaging Archive [142], both of which have been pivotal in advancing research in the genomic and imaging domains, respectively. However, despite the promotion of data-sharing practices and the availability of public repositories, longitudinal datasets in oncology remain limited. Several hurdles may be involved in acquiring and sharing longit...
work page 2024
-
[154]
Modeling Missing Data in Clinical Time Series with RNNs,
Z. C. Lipton et al., “Modeling Missing Data in Clinical Time Series with RNNs,” Mach. Learn. Healthc., vol. 56, no. 56, pp. 253–270, 2016. [155] I. M. Baytas et al., “Patient Subtyping via Time-Aware LSTM Networks,” in Proceedings of the 23rd ACM SIGKDD International Conference on Knowledge Discovery and Data Mining, in KDD ’17. New York, NY, USA: Associa...
arXiv 2016
Reviewed August 8, 2026 · model on record in the stance chip above.
Discussion (0). Continue with ORCID to comment.